JP2013511522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013511522A5 JP2013511522A5 JP2012539887A JP2012539887A JP2013511522A5 JP 2013511522 A5 JP2013511522 A5 JP 2013511522A5 JP 2012539887 A JP2012539887 A JP 2012539887A JP 2012539887 A JP2012539887 A JP 2012539887A JP 2013511522 A5 JP2013511522 A5 JP 2013511522A5
- Authority
- JP
- Japan
- Prior art keywords
- daptomycin
- containing composition
- stable
- long
- term storage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010013198 Daptomycin Proteins 0.000 claims 43
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims 43
- 229960005484 daptomycin Drugs 0.000 claims 43
- 230000007774 longterm Effects 0.000 claims 22
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 9
- 239000001110 calcium chloride Substances 0.000 claims 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims 9
- 238000004128 high performance liquid chromatography Methods 0.000 claims 6
- 239000012535 impurity Substances 0.000 claims 5
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims 4
- 239000000920 calcium hydroxide Substances 0.000 claims 4
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims 4
- 230000007062 hydrolysis Effects 0.000 claims 3
- 238000006460 hydrolysis reaction Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- 229960005069 calcium Drugs 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims 1
- 239000001527 calcium lactate Substances 0.000 claims 1
- 229960002401 calcium lactate Drugs 0.000 claims 1
- 235000011086 calcium lactate Nutrition 0.000 claims 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims 1
- 239000000347 magnesium hydroxide Substances 0.000 claims 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26369509P | 2009-11-23 | 2009-11-23 | |
| US61/263,695 | 2009-11-23 | ||
| US37180210P | 2010-08-09 | 2010-08-09 | |
| US61/371,802 | 2010-08-09 | ||
| PCT/US2010/049322 WO2011062676A1 (en) | 2009-11-23 | 2010-09-17 | Formulations of daptomycin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013511522A JP2013511522A (ja) | 2013-04-04 |
| JP2013511522A5 true JP2013511522A5 (enExample) | 2013-11-07 |
Family
ID=44059911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012539887A Pending JP2013511522A (ja) | 2009-11-23 | 2010-09-17 | ダプトマイシン製剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110124551A1 (enExample) |
| EP (1) | EP2504020A4 (enExample) |
| JP (1) | JP2013511522A (enExample) |
| CA (1) | CA2774094A1 (enExample) |
| WO (1) | WO2011062676A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012012406B1 (pt) | 2009-11-23 | 2021-11-16 | Cubist Pharmaceuticals Llc | Composições farmacêuticas sólidas de daptomicina, seu produto farmacêutico e seus métodos de fabricação |
| CA2823628A1 (en) | 2011-01-05 | 2012-07-12 | Hospira, Inc. | Spray drying vancomycin |
| RU2013157188A (ru) * | 2011-05-26 | 2015-07-10 | Кьюбист Фармасьютикалз, Инк. | Композиции св-183,315 и относящиеся к ним способы |
| DE13837694T1 (de) | 2012-09-11 | 2015-12-31 | Hospira Australia Pty Ltd. | Daptomycinformulierungen und Verwendungen davon |
| SMT201700369T1 (it) | 2013-03-13 | 2017-09-07 | Theravance Biopharma Antibiotics Ip Llc | Sali di idrocloruro di un composto antibiotico |
| CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
| CN104511011A (zh) * | 2013-09-29 | 2015-04-15 | 山东新时代药业有限公司 | 一种达托霉素无菌粉末及其制备方法 |
| CN104387444B (zh) * | 2014-11-13 | 2017-12-08 | 北大医药重庆大新药业股份有限公司 | 一种达托霉素杂质rs‑2高纯度样品的制备方法 |
| CN106943587B (zh) * | 2016-01-06 | 2021-06-22 | 山东新时代药业有限公司 | 一种注射用达托霉素冻干粉针及其制备工艺 |
| CN105699554B (zh) * | 2016-03-10 | 2017-08-01 | 杭州华东医药集团新药研究院有限公司 | 高纯度达托霉素内酯水解物及其应用 |
| WO2018073269A1 (en) | 2016-10-21 | 2018-04-26 | Xellia Pharmaceuticals Aps | Liquid formulations of daptomycin |
| MX2020001885A (es) * | 2017-08-31 | 2020-09-07 | Xellia Pharmaceuticals Aps | Formulaciones de daptomicina. |
| KR20210114000A (ko) * | 2018-12-21 | 2021-09-17 | 아레콜 리미티드 | 신규 조성물 |
| JP2022532045A (ja) * | 2019-05-10 | 2022-07-13 | クセリア ファーマシューティカルズ エーピーエス | ダプトマイシン水性製剤 |
| CN111103373B (zh) * | 2020-01-03 | 2022-04-19 | 丽珠集团福州福兴医药有限公司 | 一种达托霉素的检测方法 |
| CA3170514A1 (en) | 2020-03-12 | 2021-09-16 | Baxter International Inc. | Daptomycin formulations containing a combination of sorbitol and mannitol |
| CN114788814B (zh) * | 2021-01-26 | 2023-10-13 | 浙江创新生物有限公司 | 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用 |
| WO2025037189A1 (en) * | 2023-08-11 | 2025-02-20 | Intas Pharmaceuticals Ltd. | Daptomycin formulation |
| WO2025037188A1 (en) * | 2023-08-11 | 2025-02-20 | Intas Pharmaceuticals Ltd. | Pharmaceutical composition of daptomycin. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2011365A1 (en) * | 1989-03-06 | 1990-09-06 | Eugene L. Inman | Diluent formulation for daptomycin |
| US6696412B1 (en) * | 2000-01-20 | 2004-02-24 | Cubist Pharmaceuticals, Inc. | High purity lipopeptides, Lipopeptide micelles and processes for preparing same |
| US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
| US6716962B2 (en) * | 2000-07-17 | 2004-04-06 | Micrologix Biotech Inc. | Extractive purification of lipopeptide antibiotics |
| US20060014674A1 (en) * | 2000-12-18 | 2006-01-19 | Dennis Keith | Methods for preparing purified lipopeptides |
| AU2002246688A1 (en) * | 2000-12-18 | 2002-07-30 | Altus Biologics Inc. | Methods for preparing purified daptomycin |
| WO2002059145A1 (en) * | 2000-12-18 | 2002-08-01 | Cubist Pharmaceuticals, Inc. | Methods for preparing purified lipopeptides |
| CA2517005A1 (en) * | 2003-02-20 | 2004-09-02 | Santarus, Inc. | A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid |
| US20070202051A1 (en) * | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
-
2010
- 2010-09-17 US US12/885,009 patent/US20110124551A1/en not_active Abandoned
- 2010-09-17 JP JP2012539887A patent/JP2013511522A/ja active Pending
- 2010-09-17 CA CA2774094A patent/CA2774094A1/en not_active Abandoned
- 2010-09-17 EP EP10831938.5A patent/EP2504020A4/en not_active Withdrawn
- 2010-09-17 WO PCT/US2010/049322 patent/WO2011062676A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013511522A5 (enExample) | ||
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| CY1124262T1 (el) | Σκευασματα βενδαμουστινης | |
| CO6382125A2 (es) | Inhibidores de proteína quinasa | |
| JP2018140990A5 (enExample) | ||
| MY166045A (en) | Abeta antibody formulation | |
| JP2013520405A5 (enExample) | ||
| JP2015527402A5 (enExample) | ||
| PE20190405A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4beta7 | |
| MX2014001101A (es) | Composiciones orales que contienen un ester 17-hydroxyprogesterona y metodos relacionados. | |
| AR088380A1 (es) | Formulaciones de etanercept estabilizadas con cloruro de sodio | |
| CL2012001841A1 (es) | Polimorfo cristalino de la forma a de 2-(5-bromo-4-(4-ciclopropilnaftalen-1-il)-4h-1,2,4-triazol-3-iltio)acetato de sodio; método de preparación; composición farmacéutica; y su uso para el tratamiento o prevención de hiperuricemia o una enfermedad causada por niveles elevados de ácido úrico. | |
| CA2894891A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
| AR067701A1 (es) | Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2 | |
| JP2013545745A5 (enExample) | ||
| EA201270216A1 (ru) | Фармацевтический состав | |
| RU2016150678A (ru) | ХЛОРИДНАЯ СОЛЬ ПЕПТИДА TAT-NR2B9с, КОМПОЗИЦИЯ НА ЕГО ОСНОВЕ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2009531457A5 (enExample) | ||
| FI3777833T3 (fi) | Dopa-dekarboksylaasin estäjän koostumuksia | |
| JP2016503058A5 (enExample) | ||
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| RU2017101667A (ru) | Фармацевтические композиции | |
| RU2018114480A (ru) | Соли и твердые формы монобактамного антибиотика | |
| RU2016147362A (ru) | Препараты жидкого концетрата циклофосфамида | |
| ECSP12011699A (es) | Tableta |